Lmb-2

Skin Disorder

National Cancer Institute (NCI)antibody_drug_conjugatePhase 2Dormant

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 95/ 100

Competitive context

1 Active assets in the Skin Disorder cohort.

Asset / Sponsor	Phase	Rating
Mometasone North Central Cancer Treatment Group	Phase 3	BB
Capecitabine Binghe Xu	Phase 3	B
Docetaxel Binghe Xu	Phase 3	B
Baricitinib Eli Lilly and Company	Phase 2	B
Trabectedin Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 2	B

View all 14 →

Same molecule, other indications

Lmb-2 is also rated in:

cutaneous melanomaDormant

B

Indicative · Phase 2

57 / 100

skin carcinomaDormant

B

Indicative · Phase 2

57 / 100

B-cell chronic lymphocytic leukemiaDormant

B

Indicative · Phase 2

57 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.